Cisplatin, etoposide, bleomycin first-line therapy and early resection of residual tumor in far-advanced germinal testis cancer

G. Pizzocaro, L. Piva, R. Salvioni, F. Zanoni, A. Milani

Research output: Contribution to journalArticle

Abstract

Forty consecutive patients with far-advanced germinal testis tumors (lymph node metastases > 10 cm, pulmonary nodules > 5 cm, extrapulmonary spread, alpha-fetoprotein > 1000 ng/ml, human chorionic gonadotropin > 50,000 mIU/ml) were treated with 5 courses of cisplatin, etoposide, and bleomycin (PEB). Twenty-five patients underwent surgery for the removal of residual masses after the first 3 inductions. Fibrotic-necrotic tissue was resected in 11 cases, 12 had mature teratoma, and residual cancer was found in 2. After the combined-modality treatment, 37 patients (82.5%) entered complete remission (CR): 25 (62.5%) with PEB and 12 (30%) with PEB and complete removal of the residual tumor. One patient progressed on therapy, and 2 others had incomplete resection of the residual disease. Hematologic toxicity was moderate and gastrointestinal toxicity was very mild. After a median follow-up period of 24 months (range, 13-40), 33 patients (82.5%) remain continuously disease-free, and 4 experienced relapse. Only one of these was salvaged with further surgery and chemotherapy. First-line PEB therapy combined with early resection of residual tumor induced a very high continuous CR rate in patients with far-advanced germinal testis cancer, and toxicity was moderate.

Original languageEnglish
Pages (from-to)2411-2415
Number of pages5
JournalCancer
Volume56
Issue number10
DOIs
Publication statusPublished - 1985

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this